BNGO logo

BIONANO GENOMICS INC

BNGONASDAQ
πŸ† #4795 by market capEarnings Nov 11US Equity
$1.72β–² $0.03 (+1.78%)
After hours Β· at close
πŸ””
Track BNGO
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 1.8%
7dβ–Ό 5.5%
14dβ–² 11.0%
30dβ–² 44.5%
ytdβ–² 12.1%
1yβ–² 0.6%
🏦Market Cap
$20M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-7.4%
Declining
πŸ“ŠGross Margin
47.5%
Healthy
πŸ’΅FCF Margin
-67.9%
Thin
βš–οΈP/S Ratio
0.6x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$1.70 – $1.75
52-Week Range
$1.00 – $2.23
Volume
$2.01B
Avg Volume
$2.10B
Shares Outstanding
11.5M
Next Earnings
Oct 25, 2026

Fundamentals Snapshot

Annual Revenue
$29M
Last Q Revenue
$8M
P/E Ratio
-0.5
P/S Ratio
0.6x
EPS (TTM)
$-2.79
Dividend Yield
0.00%
Dilution (1yr)
+475.8%

Why Investors Own BNGO

  • βœ“High-growth profile β€” revenue up +47.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 61% gross margin and 11% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BNGO logo

BIONANO GENOMICS INC

BNGO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$29Mβ–Ό βˆ’7.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
22.0%β–² +1677.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$33Mβ–Ό βˆ’67.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$16Mβ–Ό βˆ’76.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
10.7Mβ–² +475.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$4Mβ–² +$14M YoY
StockOtter Β· stockotter.space

About BIONANO GENOMICS INC

Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
60/100

Analyst Ratings

β“˜
Consensus
Buy
8 analysts
Strong Buy2
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates